Our adventure is an interesting one. A company based on science and a nack for business, needs some explaining. Feel free to hear from our founders and learn more about Immundnz. Let’s start with our name, though. People often ask us how to pronounce Immundnz. So, let’s hear it!
How do you say Immundnz?
Meet our founders. Each of them has a story to tell you of where they came from and how they add to Immundnz’ expertise
Immundnz has an entrepreneurial team of highly-skilled and qualified experts in immunology, biochemistry, bio-analytical chemistry and biomarker analysis. The members have originated from a rich academic and industrial research background, bringing their experience into translation. Immundnz collaborates with many biopharma and business professionals who have experience in drug discovery and development.
Robert-Jan – Dr. Ir. Robert-Jan Lamers is Founder and Company Director of Immundnz. He has over 20 years of experience in non-clinical and preclinical research for drug discovery and development.
Masih – Dr. Masih Alam is co-Founder of Immundnz. He has worked for over 20 years in immunology and cell biology in both academic and business settings.
Rawshan – Dr. Rawshan Choudhury is Principal Scientist of Immundnz. She has worked in cell biology and protein research in various human and other mammalian tissue systems and in various therapeutic areas to study proteins for over 20 years.
Learn more about the road we traveled to and how Immundnz came to be. If you’d like to be part of our adventure, we welcome an invitation to meet, get acquainted, and lay down a new path of research. Together.
Almost 10 years ago, two befriended scientists started a joint hike in a partnership that proved to be the foundation of Immundnz’s establishment in 2016 at the prestigious Alderley Park.
To co-found Immundnz, Dr. Masih Alam and Dr. Ir. Robert-Jan Lamers both brought in considerable expertise in academics and industry, having founded businesses before.
Dr Masih Alam founded ImmunoSYS, a biological consultancy company working with industrial partners to develop South Asia’s biologics market and standards.
Dr Ir. Robert-Jan Lamers founded Abundnz in 2011, a solid analytical partner for biotech and pharma industries worldwide.
Combining their expertise, they embarked on a trip for the following years. In this time, Immundnz charted a course to build an entrepreneurial team of highly-skilled and qualified experts in immunology, biochemistry and analytical chemistry. Their goal? Translating rich academic and industrial research experience into customised commercial solutions.
Over the years, they started collaborating with many biopharma and business professionals of multinational pharmaceutical companies with experience in drug discovery, non-clinical, pre-clinical and clinical drug analysis.
As an attestation to their work, they also received two grants to advance their work in immunology:
First, the Eurostars grant in 2016 to work on human cell line-based in vitro immunology models to study drug-induced tissue damage.
Second, an H2020 grant to work on comprehensive in vitro human immune response testing of drugs.
Finally, an Innovate UK grant to develop an assay to assess susceptibility for cytokine storm in COVID-19.
Growing steadily, the team reached a significant milestone in 2017 when they moved into a fully equipped in vitro immunology lab at Alderley Park. In addition, their collaboration was strengthened on the personal level, with family visits to Peak District and the Netherlands. Finally, the team celebrated the lab’s official opening with a symposium organised by Immundnz at Alderley Park about in vitro immunology models.
The following years, Immundnz started commerical operations and thanks to our growth, Immundnz established a loyal clients portfolio and scaled up our operations, including the purchase of an additional 13 channel high-throughput flow cytometer.
Where we are headed now?
We prefer the road untraveled; that’s for sure. We aim to be recognised as the go-to partner for immune modelling and customised assay development. We’ll keep developing our strength in experimental immunology, differing from other CRO’s through unconventional design and experimental studies beyond standard assays‘ scope.
Along our trail, we hope to find like-minded scientists to share experiences and join our group.
Looking forward, Immundnz is open to partnering with companies and individuals who are experts in various sciences and associated with biotech and pharma industries.